Minggen Hu
机构：Chinese PLA General Hospital, Pancreas Centre (Canada) · ORCID：0000-0001-7933-7850
发表论文 129 篇 · 总被引 1883 次 · h-index 24
代表论文
- Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (2023 · Journal for ImmunoTherapy of Cancer · 被引 131)
- International experts consensus guidelines on robotic liver resection in 2023 (2023 · World Journal of Gastroenterology · 被引 107)
- Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS–STING pathway in hepatocellular carcinoma (2024 · International Immunopharmacology · 被引 23)
- Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study (2023 · International Journal of Surgery · 被引 21)
- Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
- Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China (2025 · Hepatology International · 被引 10)